Objective: This review has evaluated the effectiveness of pharmacological treatment of apathy in patients with Alzheimer's disease (AD).
Methods: A systematic literature search was conducted on published clinical trials assessing the effects of pharmacological treatment on apathy in AD over the last 10 years.
Results: Fourteen studies considered of good quality were included in the analysis (4 randomized controlled trials, 9 open-label studies, and 1 retrospective analysis). Cholinesterase inhibitors were investigated in 9 studies, monoaminergic compounds such as methylphenidate and modafinil in two trials and one trial, respectively, and Ginkgo biloba (EGb 761 extract) and citalopram in one study each. Cholinesterase inhibitors did not show statistical significant effect in 1 RCT study but were associated to improvement in 3 open-label studies. Methylphenidate elicited a small but significant activity accompanied by relevant side effects such as high blood pressure, cough, and osteoarticular pain. EGb 761 was well tolerated and countered apathy. Other treatments induced modest improvements or were ineffective.
Conclusions: Apathy treatment remains a challenge and there is no evident advantage of any specific pharmacotherapy tested so far. The development of controlled studies according to updated guidelines for the diagnosis of apathy in patients with AD is desirable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929376 | PMC |
| http://dx.doi.org/10.1155/2014/421385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing medicines for agitation and aggression in Alzheimer's disease.
Int Psychogeriatr
February 2015
Director National Ageing Research Institute and University of MelbourneProfessor of Ageing and Health, Former Editor in Chief and current Book Review Editor for International Psychogeriatrics, National Ageing Research Institute, Parkville, Victoria, Australia Email:
Machine Learning Recognizes Stages of Parkinson's Disease Using Magnetic Resonance Imaging.
Sensors (Basel)
December 2024
Faculty of Computer Science, Polish-Japanese Academy of Information Technology, 86 Koszykowa Street, 02-008 Warsaw, Poland.
Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD) and Parkinson's disease (PD), are debilitating conditions that affect millions worldwide, and the number of cases is expected to rise significantly in the coming years. Because early detection is crucial for effective intervention strategies, this study investigates whether the structural analysis of selected brain regions, including volumes and their spatial relationships obtained from regular T1-weighted MRI scans ( = 168, PPMI database), can model stages of PD using standard machine learning (ML) techniques. Thus, diverse ML models, including Logistic Regression, Random Forest, Support Vector Classifier, and Rough Sets, were trained and evaluated.
View Article and Find Full Text PDFMachine Learning and Statistical Analyses of Sensor Data Reveal Variability Between Repeated Trials in Parkinson's Disease Mobility Assessments.
Sensors (Basel)
December 2024
Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD 20742, USA.
Mobility tasks like the Timed Up and Go test (TUG), cognitive TUG (cogTUG), and walking with turns provide insights into the impact of Parkinson's disease (PD) on motor control, balance, and cognitive function. We assess the test-retest reliability of these tasks in 262 PD participants and 50 controls by evaluating machine learning models based on wearable-sensor-derived measures and statistical metrics. This evaluation examines total duration, subtask duration, and other quantitative measures across two trials.
View Article and Find Full Text PDFSmart Driving Technology for Non-Invasive Detection of Age-Related Cognitive Decline.
Sensors (Basel)
December 2024
Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, 1001 S McAllister Ave, Tempe, AZ 85281, USA.
Alzheimer's disease (AD) and Alzheimer's Related Dementias (ADRD) are projected to affect 50 million people globally in the coming decades. Clinical research suggests that Mild Cognitive Impairment (MCI), a precursor to dementia, offers a critical window of opportunity for lifestyle interventions to delay or prevent the progression of AD/ADRD. Previous research indicates that lifestyle changes, including increased physical exercise, reduced caloric intake, and mentally stimulating activities, can reduce the risk of MCI.
View Article and Find Full Text PDFPhytochemical and Cytotoxic Aspects of Amaryllidaceae Alkaloids in Species: A Review.
Plants (Basel)
December 2024
Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
The genus (Amaryllidaceae) currently contains 25 plant species naturally occurring in Europe and the Middle East region. These perennial bulbous plants possess well-known medicinal and ornamental qualities. Alkaloid diversity is their most distinctive phytochemical feature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!